Zydus gets USFDA nod for generic drug to treat multiple sclerosis

Zydus Lifesciences has secured USFDA approval to market Glatiramer Acetate Injection, a generic version of Copaxone, for treating relapsing forms of Multiple Sclerosis. Developed with Chemi S.p.A. and manufactured in Europe, the drug addresses a market with USD 719 million in annual sales in the US. This approval highlights Zydus' dedication to providing diverse therapeutic options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8K9ibp7
via IFTTT

Read More

Generic versions of key diabetic drug in market double in a month

Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and players in April. This makes diabetes drugs more affordable for Indian patients. Prices have dropped significantly, increasing access. Doctors are optimistic about the future. More patent expirations will further benefit patients. Semaglutide's upcoming patent expiry could revolutionize diabetes treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/I3WMt5d
via IFTTT

Read More

Mounjaro is now a heavyweight in weight-loss fight

Mounjaro, a weight-loss drug by Eli Lilly, saw a huge jump in sales after its India launch. Sales of Mounjaro injections increased significantly in April. Doctors are observing its effectiveness and side effects on Indian patients. Obesity is prevalent in India. Affordability and tolerance are key factors. Studies suggest constipation is a common side effect.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PbVD0QM
via IFTTT

Read More

Aster DM Healthcare to invest Rs 480 cr to set up new hospital in Bengaluru

Aster DM Healthcare will invest Rs 480 crore to establish a 430-bed multispecialty hospital in Sarjapur, Bengaluru. The hospital, spanning 4 lakh sq ft, will be developed in two phases, with 300 beds operational by the second half of FY27 and the remaining 130 beds by FY29.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PX0s9jY
via IFTTT

Read More

Trump's new executive orders may hit Indian Pharma exports, reshape global drug supply chains: Report

The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market, according to a report by Nuvama Research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gEMCJw8
via IFTTT

Read More

Trump's prescription: Indian drug units may face stricter check-ups

Following President Trump's executive order, the Indian pharmaceutical industry anticipates a surge in unannounced inspections by the US FDA, causing concerns about compliance and potential trade barriers. Experts suggest that companies should diversify their business and invest in innovation to mitigate risks associated with increased scrutiny and potential disruptions in API sourcing from China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EGohnge
via IFTTT

Read More

TPG to acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India

TPG Growth is set to acquire a 35% stake in SCHOTT Poonawalla from Serum Institute of India, with Novo Holdings co-investing. This deal aims to bolster the drug containment firm's growth in India and globally. Serum Institute will retain a minority stake, while SCHOTT Pharma remains the controlling stakeholder, leveraging TPG's healthcare expertise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RWZK3ov
via IFTTT

Read More